EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness analysis of population-based BRCA1/2 testing, family-history-based BRCA1/2 testing, and symptom-based screening for breast and ovarian cancer in China

Feilong Zhao, Shu Wang, Jianfei Lu, Xiangying Feng, Liwei Ran, Jianjun Yang

Frontiers in Public Health · 2025

DOI: 10.3389/fpubh.2025.1479966 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Public Health, 2025. Verfasst von Feilong Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Breast Neoplasms, Early Detection of Cancer, Genetic Testing. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The women’s cancer screening program has been operational for several years in China, primarily utilizing palpation and ultrasound. Given the proven impact of BRCA1/2 mutations on the incidence of breast and ovarian cancer, the cost-effectiveness of incorporating BRCA1/2 mutation testing into these programs, either for the entire population or through enrichment based on family history of breast and ovarian cancer, remains poorly researched.

Methods

We constructed a decision tree model to compare the cost-effectiveness of three strategies: symptom-based screening only (Symptom-only strategy), population-based BRCA1/2 testing (population-based strategy), and family-history-based BRCA1/2 testing (FH-based strategy). One-way and probability sensitivity analyses enabled model uncertainty evaluation. Outcomes included early and advanced stages of ovarian and breast cancer. Cost, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated. The target population was women at 40–60 years, the time horizon was until age 70, and the perspective was payer-based.

Results

The FH-based strategy was found to be cost-effective compared to the Symptom-only strategy (ICER: ¥185,710/QALY, gaining 0.26 days’ life expectancy). Its cost-effectiveness was significantly influenced by the risks of ovarian and breast cancer among BRCA1/2 carriers, the prevalence of BRCA1/2 mutations in the general Chinese population, the prevalence of family history of breast and ovarian cancer among Chinese women, and the prevalence of BRCA1/2 mutations in the FH-positive population. Integrating these variable distributions, the FH-based strategy showed a 76.96% probability of cost-effectiveness. The Population-based strategy was not cost-effective, whether compared to the Symptom-only strategy (ICER: ¥504,476/QALY, gaining 2.66 days’ life expectancy) or to the FH-based strategy (ICER: ¥539,476/QALY, gaining 2.41 days’ life expectancy). The prevalence of BRCA1/2 mutations in the general Chinese population was identified as the primary variable affecting its cost-effectiveness. Integrating these variable distributions, the Population-based strategy had a probability of cost-effectiveness of only 0.8%.

Conclusion

Incorporating family-history-based BRCA1/2 testing into breast and ovarian cancer screening programs is cost-effective in China and warrants promotion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsBreast NeoplasmsEarly Detection of CancerGenetic TestingMass ScreeningHumansFemaleCost-Benefit AnalysisChinaMiddle AgedAdultAgedQuality-Adjusted Life YearsDecision TreesMutationCost-Effectiveness AnalysisBRCA1 Protein

Stichwörter der Autor:innen

BRCA1BRCA2Chinabreast cancercost-effectivenessfamily historyovarian cancer

Substanzen

BRCA1 protein, humanBRCA1 Protein

Autor:innen und Institutionen

  • Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
  • State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University…
  • Institute for Hospital Management of Tsinghua University, Shenzhen, China.
  • Department of Dermatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

Zitieren

APA

Zhao, F., Wang, S., Lu, J., Feng, X., Ran, L., & Yang, J. (2025). Cost-effectiveness analysis of population-based BRCA1/2 testing, family-history-based BRCA1/2 testing, and symptom-based screening for breast and ovarian cancer in China. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2025.1479966

Vancouver

Zhao F, Wang S, Lu J, Feng X, Ran L, Yang J. Cost-effectiveness analysis of population-based BRCA1/2 testing, family-history-based BRCA1/2 testing, and symptom-based screening for breast and ovarian cancer in China. Frontiers in Public Health. 2025. doi:10.3389/fpubh.2025.1479966

BibTeX
@article{Zhao2025,
  author = {Zhao, Feilong and Wang, Shu and Lu, Jianfei and Feng, Xiangying and Ran, Liwei and Yang, Jianjun},
  title = {Cost-effectiveness analysis of population-based BRCA1/2 testing, family-history-based BRCA1/2 testing, and symptom-based screening for breast and ovarian cancer in China},
  journal = {Frontiers in Public Health},
  year = {2025},
  doi = {10.3389/fpubh.2025.1479966}
}
Kostenlos starten →